vs
Apellis Pharmaceuticals, Inc.（APLS）与索尼互动娱乐（RSI）财务数据对比。点击上方公司名可切换其他公司
索尼互动娱乐的季度营收约是Apellis Pharmaceuticals, Inc.的1.9倍（$370.4M vs $199.9M），索尼互动娱乐净利率更高（7.1% vs -29.5%，领先36.6%），索尼互动娱乐同比增速更快（41.1% vs -5.9%），过去两年索尼互动娱乐的营收复合增速更高（29.6% vs 7.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
索尼互动娱乐有限责任公司隶属于日本企业集团索尼集团，是美国的电子游戏与数字娱乐企业。该公司主打PlayStation品牌系列游戏主机及相关产品，按营收与股权投资规模计算，是全球电子游戏行业规模最大的企业。
APLS vs RSI — 直观对比
营收规模更大
RSI
是对方的1.9倍
$199.9M
营收增速更快
RSI
高出47.1%
-5.9%
净利率更高
RSI
高出36.6%
-29.5%
两年增速更快
RSI
近两年复合增速
7.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $370.4M |
| 净利润 | $-59.0M | $26.2M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 11.6% |
| 净利率 | -29.5% | 7.1% |
| 营收同比 | -5.9% | 41.1% |
| 净利润同比 | -62.2% | 70.5% |
| 每股收益（稀释后） | $-0.40 | $0.08 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSRSI
| Q1 26 | — | $370.4M | ||
| Q4 25 | $199.9M | $324.9M | ||
| Q3 25 | $458.6M | $277.9M | ||
| Q2 25 | $178.5M | $269.2M | ||
| Q1 25 | $166.8M | $262.4M | ||
| Q4 24 | $212.5M | $254.2M | ||
| Q3 24 | $196.8M | $232.1M | ||
| Q2 24 | $199.7M | $220.4M |
净利润APLSRSI
| Q1 26 | — | $26.2M | ||
| Q4 25 | $-59.0M | $5.2M | ||
| Q3 25 | $215.7M | $6.1M | ||
| Q2 25 | $-42.2M | $16.7M | ||
| Q1 25 | $-92.2M | $5.3M | ||
| Q4 24 | $-36.4M | $2.0M | ||
| Q3 24 | $-57.4M | $1.2M | ||
| Q2 24 | $-37.7M | $-100.0K |
毛利率APLSRSI
| Q1 26 | — | — | ||
| Q4 25 | — | 34.4% | ||
| Q3 25 | — | 34.0% | ||
| Q2 25 | — | 35.3% | ||
| Q1 25 | — | 34.9% | ||
| Q4 24 | — | 36.4% | ||
| Q3 24 | — | 34.8% | ||
| Q2 24 | — | 34.4% |
营业利润率APLSRSI
| Q1 26 | — | 11.6% | ||
| Q4 25 | -25.6% | 8.9% | ||
| Q3 25 | 48.7% | 7.0% | ||
| Q2 25 | -18.6% | 9.0% | ||
| Q1 25 | -50.0% | 5.6% | ||
| Q4 24 | -12.3% | 4.8% | ||
| Q3 24 | -24.0% | 2.8% | ||
| Q2 24 | -14.7% | 1.9% |
净利率APLSRSI
| Q1 26 | — | 7.1% | ||
| Q4 25 | -29.5% | 1.6% | ||
| Q3 25 | 47.0% | 2.2% | ||
| Q2 25 | -23.6% | 6.2% | ||
| Q1 25 | -55.3% | 2.0% | ||
| Q4 24 | -17.1% | 0.8% | ||
| Q3 24 | -29.2% | 0.5% | ||
| Q2 24 | -18.9% | -0.0% |
每股收益（稀释后）APLSRSI
| Q1 26 | — | $0.08 | ||
| Q4 25 | $-0.40 | $0.08 | ||
| Q3 25 | $1.67 | $0.06 | ||
| Q2 25 | $-0.33 | $0.12 | ||
| Q1 25 | $-0.74 | $0.05 | ||
| Q4 24 | $-0.30 | $0.03 | ||
| Q3 24 | $-0.46 | $0.01 | ||
| Q2 24 | $-0.30 | $0.00 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $330.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $318.6M |
| 总资产 | $1.1B | $677.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSRSI
| Q1 26 | — | $330.6M | ||
| Q4 25 | $466.2M | $342.5M | ||
| Q3 25 | $479.2M | $279.5M | ||
| Q2 25 | $370.0M | $246.4M | ||
| Q1 25 | $358.4M | $232.8M | ||
| Q4 24 | $411.3M | $233.5M | ||
| Q3 24 | $396.9M | $220.9M | ||
| Q2 24 | $360.1M | $198.4M |
股东权益APLSRSI
| Q1 26 | — | $318.6M | ||
| Q4 25 | $370.1M | $147.2M | ||
| Q3 25 | $401.2M | $133.1M | ||
| Q2 25 | $156.3M | $122.9M | ||
| Q1 25 | $164.2M | $81.3M | ||
| Q4 24 | $228.5M | $78.7M | ||
| Q3 24 | $237.1M | $69.8M | ||
| Q2 24 | $264.3M | $63.4M |
总资产APLSRSI
| Q1 26 | — | $677.3M | ||
| Q4 25 | $1.1B | $658.5M | ||
| Q3 25 | $1.1B | $593.2M | ||
| Q2 25 | $821.4M | $543.0M | ||
| Q1 25 | $807.3M | $387.0M | ||
| Q4 24 | $885.1M | $379.5M | ||
| Q3 24 | $901.9M | $362.6M | ||
| Q2 24 | $904.5M | $340.7M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $20.1M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | 0.77× |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSRSI
| Q1 26 | — | $20.1M | ||
| Q4 25 | $-14.2M | $69.1M | ||
| Q3 25 | $108.5M | $41.4M | ||
| Q2 25 | $4.4M | $25.8M | ||
| Q1 25 | $-53.4M | $28.7M | ||
| Q4 24 | $19.4M | $25.9M | ||
| Q3 24 | $34.1M | $29.4M | ||
| Q2 24 | $-8.3M | $20.2M |
自由现金流APLSRSI
| Q1 26 | — | — | ||
| Q4 25 | $-14.3M | $68.9M | ||
| Q3 25 | $108.3M | $41.2M | ||
| Q2 25 | $4.4M | $25.6M | ||
| Q1 25 | $-53.4M | $28.6M | ||
| Q4 24 | $19.3M | $25.7M | ||
| Q3 24 | — | $29.3M | ||
| Q2 24 | $-8.4M | $19.9M |
自由现金流率APLSRSI
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | 21.2% | ||
| Q3 25 | 23.6% | 14.8% | ||
| Q2 25 | 2.5% | 9.5% | ||
| Q1 25 | -32.0% | 10.9% | ||
| Q4 24 | 9.1% | 10.1% | ||
| Q3 24 | — | 12.6% | ||
| Q2 24 | -4.2% | 9.0% |
资本支出强度APLSRSI
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 0.1% | ||
| Q3 25 | 0.0% | 0.1% | ||
| Q2 25 | 0.0% | 0.1% | ||
| Q1 25 | 0.0% | 0.1% | ||
| Q4 24 | 0.0% | 0.1% | ||
| Q3 24 | 0.0% | 0.1% | ||
| Q2 24 | 0.0% | 0.2% |
现金转化率APLSRSI
| Q1 26 | — | 0.77× | ||
| Q4 25 | — | 13.17× | ||
| Q3 25 | 0.50× | 6.84× | ||
| Q2 25 | — | 1.55× | ||
| Q1 25 | — | 5.40× | ||
| Q4 24 | — | 12.79× | ||
| Q3 24 | — | 24.74× | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
RSI
暂无分部数据
